CIK 0001023024 · Large accelerated filer
ANI PHARMACEUTICALS INC
Sign in to watch- Ticker
- ANIP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 582301143
- Phone
- 6097591810
- Business address
- 104 CARNEGIE CENTER DRIVE SUITE 300, PRINCETON, NJ, 08540
- Former names
- BIOSANTE PHARMACEUTICALS INC, BEN ABRAHAM TECHNOLOGIES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,939,756
- in 9 filings, $1.9M under 10b5-1 plans
Net −$1,939,756. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-11-16 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −6,448 | $51.66 | $333K | 995,620 |
| 2023-11-16 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −6,448 | $51.66 | $333K | 996,430 |
| 2023-11-15 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −7,647 | $53.64 | $410K | 1,002,068 |
| 2023-11-15 | Davis Krista SVP, CHIEF HR OFFICER | Sale | −2,622 | $53.81 | $141K | 32,587 |
| 2023-11-15 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −7,647 | $53.64 | $410K | 1,002,878 |
| 2023-11-14 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −22,905 | $53.17 | $1.2M | 1,009,715 |
| 2023-11-14 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −22,095 | $53.17 | $1.2M | 1,010,525 |
| 2023-11-13 | Cook Meredith SR. VP, GENERAL COUNSEL & SEC. | Sale 10b5-1 | −250 | $52.03 | $13K | 37,549 |
| 2023-11-10 | Mutz Christopher HEAD OF RARE DISEASE | Sale | −3,000 | $52.47 | $157K | 63,607 |
| 2023-10-19 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −10,000 | $57.06 | $571K | 1,032,620 |
| 2023-10-18 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −6,242 | $57.78 | $361K | 1,042,620 |
| 2023-10-17 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −8,758 | $58.53 | $513K | 1,048,862 |
| 2023-10-16 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −13,063 | $58.31 | $762K | 1,057,620 |
| 2023-10-13 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −11,937 | $57.58 | $687K | 1,070,683 |
| 2023-10-02 | Gassert Chad SVP - CORP. DEV. & STRATEGY | Sale 10b5-1 | −20,000 | $56.48 | $1.1M | 293,226 |
| 2023-09-19 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −25,333 | $61.23 | $1.6M | 1,082,620 |
| 2023-09-18 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −8,425 | $61.64 | $519K | 1,107,953 |
| 2023-09-15 | Shanmugam Muthusamy HEAD OF R&D, COO-NOVITIUM OPS | Sale 10b5-1 | −16,242 | $62.81 | $1.0M | 1,116,378 |
| 2023-09-12 | Davis Krista SVP, CHIEF HR OFFICER | Shares withheld for taxes | −1,486 | $61.91 | $92K | 35,209 |
| 2023-09-08 | Lalwani Nikhil PRESIDENT & CEO | Shares withheld for taxes | −3,646 | $61.94 | $226K | 349,744 |
Page 17 of 23 · 442 trades